Quantcast

Posts related to ‘Drug companies’

Pills

Forest Labs Sputters on Patent Expiration

Posted: January 15, 2013 at 7:44 am

Forest Laboratories Inc. (NYSE: FRX) reported third-quarter fiscal 2013 results before markets opened this morning. The drug maker and marketer reported an adjusted diluted earnings per share (EPS) loss of ...
Read Full Story »
biotech

More Hope for Cancer Vaccines in 2013 (UBS, GSK, DNDN, AMGN)

Posted: January 14, 2013 at 10:04 am

Cancer ranks on the list of global killers as number two. Over the years, great strides have been made not only in cancer treatment but in survival rates for many different ...
Read Full Story »
health care

More Flu Season Stock Winners (HITK, PTX, PRGO)

Posted: January 14, 2013 at 9:09 am

The 2012 to 2013 flu season has reached what is officially at pandemic levels. The government report last week showed that more than 7% of the deaths in the prior ...
Read Full Story »
biotech

Can Dendreon’s Stock Really Double Again?

Posted: January 11, 2013 at 2:16 pm

Dendreon Corp. (NASDAQ: DNDN) is seeing shares surge higher on Friday on an analyst upgrade. The move higher is part because Dendreon has a long history of boom and bust ...
Read Full Story »
biotech

ArQule Fails in Colorectal Cancer Trials

Posted: January 11, 2013 at 9:09 am

ArQule Inc. (NASDAQ: ARQL) is about to lose some serious hope for investors. It and Daiichi Sankyo announced that the top-line results of phase 2 trial with tivantinib in colorectal cancer did not meet ...
Read Full Story »
pills

Lou Gehrig’s Disease Drug Failure Crushes Biogen Idec

Posted: January 3, 2013 at 9:04 am

Biogen Idec Inc. (NASDAQ: BIIB) is living up to why we just said it is now an overvalued biotech stock for 2013. Biogen Idec and the other biotech giants had risen perhaps too ...
Read Full Story »
biotech

Alexza FDA Approval: Coal in the Christmas Stocking?

Posted: December 24, 2012 at 11:52 am

Alexza Pharmaceuticals, Inc. (NASDAQ: ALXA) is seeing its shareholders get nothing but coal for Christmas this year. The stock is the largest loser on the NASDAQ today with a drop ...
Read Full Story »
Stock Split Image

How Overvalued Are the Biggest Biotechs? (AMGN, BIIB, GILD, ALXN)

Posted: December 20, 2012 at 2:57 pm

The largest biotech stocks have been great performers in 2012. The question is whether that can be sustained in 2013. If Wall St. analysts are correct, biotech and biohealth investors ...
Read Full Story »
biotech

Nine Big Expected Biotech Winners for 2013 (ARIA, CBST, INCY, JAZZ, MDVN, ONXX, THRX, VPHM, VVUS)

Posted: December 20, 2012 at 6:21 am

24/7 Wall St. is looking for the next great biotech stocks for 2013 after great gains have been seen in 2012. If you look at the consensus price targets from ...
Read Full Story »
pills

Drug Maker Staging a Comeback After Yesterday’s Debacle

Posted: December 14, 2012 at 11:54 am

Drug developer Rigel Pharmaceuticals Inc. (NASDAQ: RIGL) watched its shares plummet 35% yesterday following a report that rheumatoid arthritis treatment it was developing with AstraZeneca plc (NYSE: AZN) did not ...
Read Full Story »
biotech

Amgen Shakes Things Up: Dividend Boost, New Chairman, Share Buybacks

Posted: December 14, 2012 at 8:09 am

Biotech giant Amgen Inc. (NASDAQ: AMGN) made a series of moves after markets closed last night that appear to add up to an effort giving something to everybody. First out ...
Read Full Story »
pills

Teva Fails To Impress At Its Investor Meeting, Restructuring Awaits

Posted: December 11, 2012 at 2:53 pm

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is not getting any great warm welcome out of its 2012 investor meeting webcast. The company may soon find itself in a position where ...
Read Full Story »
pills

Will National Legalized Marijuana Help or Hurt Big Pharma, Tobacco and Alcohol?

Posted: December 11, 2012 at 8:13 am

On December 7, marijuana became legal in the state of Washington, adding to the list of states that have moved toward legalizing or decriminalizing the drug. Will this be a ...
Read Full Story »
Pills

J&J Gets Broader Use for Prostate Cancer Drug

Posted: December 10, 2012 at 2:01 pm

Johnson & Johnson (NYSE: JNJ) may have an even larger winner with its prostate cancer drug called ZYTIGA. The Food & Drug Administration has approved an expanded indication in men ...
Read Full Story »
pills

Amarin Takes on More Debt, Shares Suffer

Posted: December 7, 2012 at 9:21 am

Biopharmaceutical company Amarin Corp. PLC (NASDAQ: AMRN) announced after markets closed last night that it has received $100 million in nonequity financing from an investment fund managed by Pharmakon Advisors. ...
Read Full Story »